Dicerna pharmaceuticals, inc. (DRNA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue

34,028

7,080

8,035

5,682

3,107

1,541

1,545

1,545

1,545

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

162

-

-

-

-

184

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

43,171

34,818

30,086

22,832

21,603

13,773

11,695

10,339

9,893

9,562

8,527

9,068

8,743

9,042

10,061

11,032

11,264

11,262

12,142

11,875

8,692

9,907

7,489

6,806

5,251

4,197

2,430

2,513

2,418

General and administrative

16,023

13,625

10,619

8,831

9,676

7,236

5,354

4,760

4,335

3,139

4,137

4,066

5,496

1,955

4,338

4,656

4,484

4,419

4,857

4,519

5,445

4,710

3,725

4,372

2,841

2,240

1,302

1,142

1,136

Litigation expense

-

-

0

0

-

10

3,694

22,244

3,184

-

2,548

2,234

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating expenses

59,194

48,443

40,705

31,663

31,279

21,030

20,743

37,343

17,412

16,950

15,212

15,368

14,239

13,913

14,399

15,688

15,748

15,681

16,999

16,394

14,137

14,617

11,214

11,178

8,092

6,437

3,732

3,655

3,554

Loss from operations

-25,166

-41,363

-32,670

-25,981

-28,172

-19,489

-19,198

-35,798

-15,867

-15,920

-15,212

-15,368

-14,239

-14,075

-14,237

-15,688

-15,748

-15,681

-16,999

-16,210

-14,137

-14,617

-11,214

-11,178

-8,092

-6,437

-3,732

-3,655

-3,554

Other income (expense):
Preferred stock warrant liability re-measurement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,118

0

0

-2,559

-99

96

-118

-5

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-143

-

-

-318

-

-

Interest income

2,613

1,503

1,880

2,136

2,018

1,083

401

330

288

179

179

143

38

53

61

66

55

46

55

34

53

30

21

8

4

-

1

-

0

Interest expense

4

3

0

0

0

-

223

176

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

42

157

192

241

249

270

Other income

65

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other income, net

2,674

1,693

1,880

2,136

2,018

-

178

154

-

-

179

143

-

-

-

-

-

-

-

-

-

30

21

-177

-2,712

-282

-462

-131

-265

Net loss

-22,492

-39,670

-30,790

-23,845

-26,154

-18,610

-19,020

-35,644

-15,579

-15,741

-15,033

-15,225

-14,201

-14,022

-14,176

-15,622

-15,693

-15,635

-16,944

-16,176

-14,084

-14,587

-11,193

-11,355

-10,804

-6,719

-4,194

-3,786

-3,819

Foreign currency translation adjustment

-

-

-3

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-

-

-30,793

-

-

-

-19,020

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Redeemable Preferred Stock Dividends

-

-

-

-

-

-

-

-

-

-

4,111

2,622

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred Stock Conversions, Inducements

-

-

-

-

-

-

-

-

-

-

-

6,144

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Less: accretion and dividends on redeemable convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

204

9

346

1,022

1,011

Net Income (Loss) Available to Common Stockholders, Basic

-

-

-

-

-

-

-

-

-

-

-19,144

-23,991

-

-

-14,176

-15,622

-

-

-

-

-

-14,587

-11,193

-11,355

-11,008

-6,728

-4,540

-4,808

-4,830

Net loss per share – basic and diluted (in dollars per share)

-0.31

-0.58

-0.45

-0.35

-0.38

-0.27

-0.35

-0.68

-0.30

-0.91

-0.92

-1.15

-0.68

-0.68

-0.68

-0.75

-0.76

-0.62

-0.82

-0.86

-0.79

-0.71

-0.63

-0.64

-1.02

-204.09

-161.55

-171.13

-172.80

Weighted average common shares outstanding – basic and diluted (in shares)

72,919

68,768

68,360

68,323

68,259

63,385

54,799

52,555

51,723

25,242

20,841

20,794

20,791

20,753

20,752

20,726

20,646

24,021

20,592

18,852

17,815

18,066

17,706

17,684

10,822

33

28

28

27